Cogent Biosciences, Inc. (COGT) company profile
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
About Cogent Biosciences
Pharmaceutical Preparations, SIC 2834
Cogent Biosciences, Inc. is a biotechnology company focused on discovering and developing therapeutic drug candidates. The company's principal development program centers on bezuclastinib, a targeted product candidate undergoing clinical trials, alongside several early-stage discovery and preclinical research programs. Cogent Biosciences designs its drug candidates to address specific clinical conditions, targeting patient populations in need of novel treatments. The company aims to provide its therapies to healthcare providers, physicians, patients, and third-party healthcare payors upon receiving necessary regulatory approvals.
The company is incorporated in Delaware and maintains its corporate headquarters in Waltham, Massachusetts. Its physical footprint includes leased office and laboratory facilities located in Waltham, Massachusetts, and Boulder, Colorado. Cogent Biosciences conducts its drug development operations primarily in the United States, coordinating clinical trials, regulatory submissions, and research activities with regulatory authorities such as the Food and Drug Administration.
Summary of the business section of Cogent Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cogent Biosciences, Inc.
- Founded
- 2014
- Headquarters
- Waltham, MA
- Address
- 180 Third Avenue, 4th Floor
- Phone
- (617) 945-5576
- Website
- www.cogentbio.com
- Employees
- 258, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- COGT
- Former tickers
- UMRX until Nov 9, 2020
- Exchange
- Nasdaq
- IPO date
- Mar 29, 2018
- Shares outstanding
- 174M, Aug 6, 2026
- Public float
- $772.90M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-4 reverse, Nov 9, 2020
- SEC CIK
- 1622229
- CUSIP
- 19240Q201
- ISIN
- US19240Q2012
- FIGI
- BBG007DHZQR7
- Share class FIGI
- BBG007DHY102
- EIN
- 46-5308248
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew R. Robbins | President and CEO, Director | 657,503 |
| Evan Kearns | Chief Legal Officer | 109,398 |
| John Edward Robinson | Chief Scientific Officer | 140,002 |
| Jessica Sachs | Chief Medical Officer | 133,938 |
| John L. Green | Chief Financial Officer | 131,834 |
| Cole Pinnow | Chief Commercial Officer | 97,450 |
| Karen Jean Ferrante | Director | – |
| Arlene Morris | Director | 45,510 |
| Christopher W. Cain | Director | – |
| Matthew Ros | Director | – |
| Todd Shegog | Director | – |
| Peter Evan Harwin | Director | – |
| Funds Management LLC Fairmount | Director | 5,503,418 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $27.76M | $116.77M | $8.93M | $414 | $121 |
| FY2024 | $4.92M | $11.88M | $2.34M | $91 | $91 |
| FY2023 | $7.90M | -$201.50K | $2.99M | $69 | $92 |
| FY2022 | $4.39M | $9.82M | $1.89M | $135 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Andrew Robbins Chief Executive Officer | $724.55K | $21.60K | $12.99M | $13.45M | $561.60K | $14.00K | $27.76M | +465% |
| John Green Chief Financial Officer | $510.68K | $11.47K | $3.97M | $3.75M | $298.13K | $14.00K | $8.55M | +389% |
| Jessica Sachs Chief Medical Officer | $549.39K | $12.34K | $4.54M | $3.75M | $320.89K | $14.00K | $9.18M | +401% |
| Cole Pinnow Chief Commercial Officer | $482.27K | $9.57K | $4.54M | $3.55M | $248.77K | $14.00K | $8.84M | +123% |
| John Robinson Chief Scientific Officer | $532.04K | $11.95K | $4.54M | $3.75M | $310.76K | $14.00K | $9.15M | +406% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 29, 2018
- Offer price
- $12.00
- Securities offered
- 5,770,000
- Gross proceeds
- $69.24M
- Exchange
- Nasdaq
- First trading day
- Mar 29, 2018
- First-day close
- $11.11-7.4%
- Lock-up ends (est.)
- Sep 25, 2018
“The initial public offering price per share of our common stock is $12.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 258 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 9, 2020 | Merger vote | Definitive merger proxy statement |
| Oct 5, 2020 | Name change | Name changed from Unum Therapeutics Inc. to Cogent Biosciences, Inc. |
| Sep 3, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 6, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 6, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 29, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 26, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?